title: The Ids have it.
abstract: In this issue of Cancer Cell, Anido et al. demonstrate that Id1 is the likely arbiter of divergent transforming growth factor-β (TGF-β) signaling in glioma-initiating cells (GICs) from different tumors. These findings hold both the promise and potential peril of therapeutic targeting of the TGF-β pathway.
authors.affiliation: Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Lincoln A
authors.initials: LA
authors.lastname: Edwards
authors.forename: Howard A
authors.initials: HA
authors.lastname: Fine